- Home
- ACAD vs PLMR Comparison
ACAD vs PLMR Comparison
Compare ACAD & PLMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PLMR
- Stock Information
- Founded
- ACAD 1993
- PLMR 2013
- Country
- ACAD United States
- PLMR United States
- Employees
- ACAD N/A
- PLMR N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PLMR Property-Casualty Insurers
- Sector
- ACAD Health Care
- PLMR Finance
- Exchange
- ACAD Nasdaq
- PLMR Nasdaq
- Market Cap
- ACAD 3.8B
- PLMR 3.8B
- IPO Year
- ACAD 2004
- PLMR 2019
- Fundamental
- Price
- ACAD $20.98
- PLMR $135.01
- Analyst Decision
- ACAD Buy
- PLMR Buy
- Analyst Count
- ACAD 18
- PLMR 8
- Target Price
- ACAD $27.71
- PLMR $163.57
- AVG Volume (30 Days)
- ACAD 2.0M
- PLMR 294.6K
- Earning Date
- ACAD 08-05-2025
- PLMR 08-04-2025
- Dividend Yield
- ACAD N/A
- PLMR N/A
- EPS Growth
- ACAD N/A
- PLMR 43.71
- EPS
- ACAD 1.37
- PLMR 5.02
- Revenue
- ACAD $996,283,000.00
- PLMR $609,961,000.00
- Revenue This Year
- ACAD $13.39
- PLMR $254.96
- Revenue Next Year
- ACAD $10.59
- PLMR $21.21
- P/E Ratio
- ACAD $15.33
- PLMR $26.90
- Revenue Growth
- ACAD 22.42
- PLMR 50.51
- 52 Week Low
- ACAD $13.40
- PLMR $81.37
- 52 Week High
- ACAD $25.23
- PLMR $175.85
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- PLMR 29.79
- Support Level
- ACAD $20.75
- PLMR $141.22
- Resistance Level
- ACAD $23.09
- PLMR $148.53
- Average True Range (ATR)
- ACAD 0.78
- PLMR 5.68
- MACD
- ACAD -0.20
- PLMR -1.84
- Stochastic Oscillator
- ACAD 9.83
- PLMR 0.88
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PLMR Palomar Holdings Inc. Common stock
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.